CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
diclofenac potassium (XP21L) +1 moredrug
Likely dose
diclofenac potassium (XP21L) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00375934
NCT00375934Phase 3Completed
CompareCT.gov

Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery

Xanodyne Pharmaceuticals·interventional·Posted Sep 13, 2006·Updated Sep 21, 2010

In Brief

A Phase 3 clinical trial evaluating diclofenac potassium (XP21L) and Placebo for Pain, Postoperative. Completed, enrolled 200 participants across 4 sites.

Detailed Summary

A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 13, 2006
Enrollment StartSep 1, 2006
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 19.8 years ago

Interventions

diclofenac potassium (XP21L)drug

25 mg capsule, every 6 hours

Placebodrug

Oral placebo capsule, every 6 hours